Biotech, Partnering, Pharma

CureVac and Sanofi sign a pharma licensing agreement

Posted on 02 July 2014

Tags: , , ,

CureVac announced the execution of a an exclusive pharma licensing agreement with Sanofi Pasteur to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen.

In 2011, CureVac and Sanofi Pasteur signed a collaboration and license option agreement for several pre-defined pathogens.

CureVac met all pre-agreed milestones and acceptance criteria relating to these agreements, and therefore Sanofi Pasteur exercised its first option and extended its exclusive and non-exclusive options on all five pathogens.

Sanofi Pasteur will fund all research, development, manufacturing and commercialization activities and will have exclusive worldwide marketing rights for the RNActive vaccine.

CureVac will receive an undisclosed upfront payment from Sanofi Pasteur for the option exercise and an additional payment for extending the option term for the other pathogens.

In addition, CureVac is eligible for additional milestone payments up to 150.5 million for achieving several clinical, regulatory and commercial milestones, as well as royalty payments associated with products sales of RNActive vaccines.

The exclusive license agreement for the development and commercialization of an mRNA-based vaccine is also a result of the positive and still ongoing four-year $33.1 million research collaboration of CureVac with Sanofi Pasteur and In-Cell-Art, co-funded by the U.S. Defense Advanced Research Projects Agency (DARPA), as announced in November 2011.

Additional details of the collaboration were not disclosed.

For further deal information visit Current Agreements (subscription required)

 

Related

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitte

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e80banner300x150animgif
cabannerad300x150new4gif
e80banner300x150animgif
a1banner300x150animgif